Collection of Prescription Drug Data from MA-PD, PDP and Fallout Plans/Sponsors for Medicare Part D Payments (CMS-10174) - IRA

ICR 202306-0938-007

OMB: 0938-0982

Federal Form Document

Forms and Documents
Document
Name
Status
Supplementary Document
2023-07-17
Supplementary Document
2023-07-17
Supporting Statement A
2023-07-17
ICR Details
0938-0982 202306-0938-007
Received in OIRA 202108-0938-009
HHS/CMS CM-CPC
Collection of Prescription Drug Data from MA-PD, PDP and Fallout Plans/Sponsors for Medicare Part D Payments (CMS-10174) - IRA
Revision of a currently approved collection   No
Regular 07/18/2023
  Requested Previously Approved
36 Months From Approved 02/28/2025
1,499,065,636 1,499,238,090
62,918 2,998
0 0

CMS requires contracted Part D providers to submit prescription drug event (PDE) records as required by the Medicare Prescription Drug Improvement, and Modernization Act of 2003. The PDE data is then used in the Payment Reconciliation System to perform the annual Part D payment reconciliation, any PDE data within the Coverage Gap Phase of the Part D benefit is used for invoicing in the CGDP, and the data are part of the report provided to the Secretary of the Treasury for Section 9008. Section 11102 of the Inflation Reduction Act of 2022 establishes a Part D inflation rebate by manufacturers of certain single source drugs and biologicals with prices increasing at a rate faster than the rate of inflation. CMS will use data reported under sections 1860D-15(c)(1)(C) and (d)(2), in part, to rank drugs by total expenditures under Part D in order to select drugs for negotiation and to identify units to calculate inflation rebates. We also intend to use the PDE data submissions from Part D sponsors to fulfill our statutory obligations under the Social Security Act. This includes the use of PDE data to fulfill obligations or operationalize any future legislative changes to the Social Security Act that impact the Part D program. CMS is notifying users that it will also use data reported under sections 1860D-15(c)(1)(C) and (d)(2) to implement the Medicare Drug Negotiation Program and to calculate inflation rebates as required by the Inflation Reduction Act of 2022, as well as to fulfill our statutory obligations under the Social Security Act. This includes the use of PDE data to fulfill obligations or operationalize any future legislative changes to the Social Security Act that impact the Part D program.

Statute at Large: 18 Stat. 1860
   PL: Pub.L. 108 - 173 101 Name of Law: Medicare Prescription Drug, Improvement, and Modernization Act of 2003
   PL: Pub.L. 117 - 169 11001 Name of Law: Inflation Reduction Act of 2022
  
PL: Pub.L. 117 - 169 11001 Name of Law: Inflation Reduction Act of 2022

Not associated with rulemaking

  88 FR 27896 05/03/2023
88 FR 45428 07/17/2023
Yes

  Total Request Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 1,499,065,636 1,499,238,090 856 0 -173,310 0
Annual Time Burden (Hours) 62,918 2,998 59,920 0 0 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
No
No
The Part D contracts have increased from 739 to 856 and the average number of PDE submissions per year decreased. The adjustment decreases our response figure by 173,310 responses CMS will expand the PDE file layouts from their current 512-byte length to 1000 bytes, to be implemented effective January 1, 2025. This expansion is being implemented to accommodate future business needs, including but not limited to, updates necessary for the IRA. This new one time expansion adds 59,920 burden hours to the total burden of the package.

$13,000,000
No
    Yes
    No
No
No
No
No
Stephan McKenzie 410 786-1943 stephan.mckenzie@cms.hhs.gov

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
07/18/2023


© 2024 OMB.report | Privacy Policy